Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 6/20 | 0.60 |
| ▸ | PGK2 | P07205 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | PTPRB | P23467 | 2/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
| ▸ | ACP3 | P15309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13742442 | 0.94 | PGK1 (0.60) | PGK1PGK2SMN1; SMN2KDM4EMMP2 | |
| SCHEMBL11320696 | 0.92 | PGK1 (0.62) | PGK1PGK2SMN1; SMN2KDM4EMMP2 | |
| SCHEMBL18957741 | 0.82 | PGK1 (0.54) | PGK1PGK2SMN1; SMN2PTPRB | |
| SCHEMBL11121515 | 0.78 | PGK1 (0.52) | PGK1PGK2SMN1; SMN2KDM4EMMP2 | |
| SCHEMBL11452448 | 0.72 | PGK1 (0.48) | PGK1PGK2SMN1; SMN2KDM4EMMP2 | |
| SCHEMBL6519625 | 0.72 | PGK1 (0.48) | PGK1PGK2SMN1; SMN2KDM4EMMP2 | |
| SCHEMBL12606470 | 0.72 | PGK1 (0.48) | PGK1PGK2SMN1; SMN2 | |
| SCHEMBL11306957 | 0.70 | PGK1 (0.69) | PGK1PGK2SMN1; SMN2THRBPTPRB | |
| SCHEMBL13512948 | 0.69 | PGK1 (0.44) | PGK1PGK2SMN1; SMN2KDM4EMMP2 | |
| SCHEMBL9168205 | 0.69 | SMN1; SMN2 (0.56) | PGK1PGK2SMN1; SMN2KDM4EMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027398-B1 | LIGHT-EMITTING DENDRIMERS AND DEVICES | ISIS INNOVATION (GB) | 2004-06-09 | — | — | EP | disclosed |
| US-6720093-B2 | DEVICE INCORPORATING AS, OR IN, ITS LIGHT-EMITTING ELEMENT LUMINESCENT COMPOUND INCLUDING CONJUGATED DENDRITIC MOLECULAR STRUCTURE COMPRISING GROUPS SELECTED FROM ARYL AND HETEROARYL GROUPS AND ALKENYL GROUPS CONNECTED TO EACH OTHER | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2004-04-13 | — | — | US | disclosed |
| US-20030165716-A1 | Dendrimers according to present invention which can be used for incorporation into light emitting devices have core and/or branches comprising electroluminescent or charge-transporting chromophores (conjugated units) | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6558818-B1 | Light-emitting dendrimers and devices | ISIS INNOVATION LTD. (GB) | 2003-05-06 | — | — | US | disclosed |
| EP-1027398-A1 | LIGHT-EMITTING DENDRIMERS AND DEVICES | ISIS INNOVATION LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021935-A1 | LIGHT-EMITTING DENDRIMERS AND DEVICES | ISIS INNOVATION LIMITED (GB) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030165716-A1 | Dendrimers according to present invention which can be used for incorporation into light emitting devices have core and/or branches comprising electroluminescent or charge-transporting chromophores (conjugated units) | CLTB, CLTA, CLTC | PGK1 4787/4885PGK2 4564/4885SMN1; SMN2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.